Sinustop

Quick links to important sections

Sinustop

Method of action: Antitussive, Nasal Preparations

Treatment option: Blocked Nose, Cold

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinustop

Quick Facts

Property Description
Active ingredient Pseudoephedrine hydrochloride
Form Oral solid preparation (tablet/capsule)
Pharmacological class Systemic Decongestant
Common use Relief of nasal and sinus congestion
Origin Synthetic compound (Sympathomimetic amine)

What Type of Medicine is Sinustop and What is its Core Ingredient?

The medicine known as Sinustop is fundamentally classified as a systemic decongestant, a type of pharmaceutical product used to alleviate congestion and pressure throughout the upper respiratory tract. Its composition is defined by its active pharmaceutical ingredient, Pseudoephedrine hydrochloride, a synthetic compound belonging to the pharmacological class of sympathomimetic amines. Pharmacological studies have clinically recognized this ingredient for its efficacy in managing symptoms related to temporary airway congestion. It is primarily administered through the oral route as an oral solid dosage form, such as a tablet or capsule, allowing for a sustained systemic effect. Sinustop is specifically positioned for patients seeking effective relief from congestion that affects both the nasal passages and deeper sinus areas.

What is the General Purpose of Sinustop’s Action?

The primary, general purpose of Sinustop is to offer temporary relief from the feeling of blockage and pressure associated with swollen nasal and sinus tissues. This relief is achieved because Pseudoephedrine acts as a vasoconstrictor, a key action that is well-supported by scientific literature. This mechanism involves signaling the small blood vessels lining the mucous membranes to narrow. This physiological effect reduces the blood flow, leading to a consequent decrease in local swelling and fluid accumulation. By focusing on the structural cause of the swelling, the medicine addresses the discomfort of congestion, providing the general benefit of improved patency of the airways.

What side effects are possible with Sinustop?

Possible Side Effects and Safety Information

The official safety profile for Sinustop, which contains Pseudoephedrine hydrochloride, organizes potential reactions based on their frequency and the body systems they affect, reflecting classifications made by government regulatory bodies.


Adverse Reaction Classifications

Side effects are formally classified based on the incidence observed in clinical use and post-marketing surveillance. Common adverse reactions documented in official labeling primarily affect the nervous and cardiovascular systems. These include insomnia, nervousness, restlessness, tachycardia (increased heart rate), and hypertension (high blood pressure). Other frequently listed effects include dry mouth and nausea.

Less common or rare adverse reactions are also officially documented. These rare, but clinically serious, outcomes include severe cardiovascular events such as hypertensive crisis, myocardial infarction (heart attack), and cerebral hemorrhage (stroke). Other documented serious reactions include seizures and severe skin reactions.


Safety Considerations and Restrictions

Official regulatory information identifies specific groups that carry an increased risk. Older adults may be more susceptible to central nervous system effects, such as confusion and hallucinations. The sympathomimetic nature of the medicine imposes specific safety limitations, including restrictions for use in individuals with severe or uncontrolled hypertension or severe coronary artery disease.

Regulatory documents also define critical restrictions related to concomitant use: the drug is strictly prohibited for use within 14 days of taking a Monoamine Oxidase Inhibitor (MAOI) due to the high risk of a severe hypertensive crisis. The overall risk profile is considered to be related to both the dose administered and the duration of therapy.

Overdose and Emergency Response

The official regulatory profile for a Sinustop (Pseudoephedrine hydrochloride) overdose is defined by the risks associated with excessive sympathomimetic activity. Documented clinical presentations include marked central nervous system (CNS) stimulation, such as agitation, confusion, psychoses, and tremors. Cardiovascular effects frequently described are tachycardia, hypertension, and palpitations. In some cases, metabolic changes like hyperglycaemia and hypokalaemia are also officially noted in regulatory documentation.

Overdose presents the risk of severe, life-threatening outcomes. These complications include seizures, myocardial infarction, and intracranial haemorrhage. The regulatory labeling also specifies the risk of rare, serious cerebrovascular conditions such as Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS).

Regulators mandate that patients seek immediate medical help or contact a Poison Control Center right away for a suspected overdose. Urgent medical assistance is required if symptoms indicative of severe events, such as a sudden severe headache or visual disturbances, occur. Management is described as supportive and symptomatic, focusing on necessary measures to maintain respiration and control convulsions, with the potential use of acid diuresis or dialysis for accelerated elimination. Population-specific notes indicate that both children and the elderly are more susceptible to adverse effects.

Therapeutic Uses of Sinustop

Sinustop is a combination medication indicated for the temporary management of symptoms related to the common cold, hay fever, and upper respiratory allergies. The therapeutic application focuses on two main areas: respiratory congestion and mucus management.

It is utilized to assist in the temporary relief of nasal and sinus congestion and the associated pressure. The medication helps to promote drainage in the nasal and sinus passages, which can assist in restoring freer breathing through the nose.

Sinustop also serves as an expectorant, with a primary use being to support the clearance of the respiratory tract. It can help to loosen and thin bronchial secretions and mucus within the airways. This action makes coughs more productive and aids the body in ridding the bronchial passageways of bothersome mucus. It is intended for short-term use to address acute symptoms and does not address the underlying cause of the condition.

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults and adolescents 12 years of age and older.

Populations for whom use is not recommended (if applicable): Children under 6 years of age are generally prohibited. Use is also not generally recommended for pregnant or breastfeeding women.

Populations for whom use is contraindicated: Patients with severe hypertension, severe coronary artery disease, narrow-angle glaucoma, or urinary retention must not use this medicine. Use is also prohibited for those with a known hypersensitivity or those who have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days.

Age-related eligibility rules: Use is strictly contraindicated in children under 6 years. For specific products, safety has not been established in children under 12 or in older adults.

Condition-specific eligibility rules: Caution is advised for patients with diabetes mellitus, prostatic hypertrophy, controlled hypertension, and mild-to-moderate hepatic or renal impairment.

Pregnancy and lactation eligibility status (if explicitly documented): Use during pregnancy and while breastfeeding is not generally recommended by regulators.

Eligibility-related restrictions: Prohibition on use within 14 days of taking an MAOI.


Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated (Absolute Prohibition); Not Recommended (Strong Restriction); Use with Caution (Conditional Restriction); Not Established (Data Insufficient).

Regulatory basis (EMA / FDA / etc.): EMA Summary of Product Characteristics; FDA Prescribing Information.

Eligibility-context constraints (as defined in official documents): Comorbidity Status; Concomitant Drug Use; Physiological State; Age Group.


Resulting Eligibility Structure

Official eligibility statements:

  • Contraindicated in patients with severe hypertension and severe coronary artery disease.
  • Use is generally contraindicated in children under 6 years of age.
  • Use is not generally recommended in pregnant or breastfeeding women.

Connection to the overall eligibility profile (2–4 sentences): The regulatory documents define who can and cannot use the medicine by establishing clear contraindications that prohibit use based on severe pre-existing cardiovascular conditions and the concurrent use of MAOIs. They further delineate eligibility through age-based restrictions, limiting use in the pediatric population, and mandate conditional use for patients with specific metabolic or organ function impairments.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Sinustop (Pseudoephedrine)


Interaction scope

Category Description based on Regulatory Documents
Medicinal product categories with documented interactions Monoamine Oxidase Inhibitors (MAOIs), other Sympathomimetic Decongestants, Ergot Alkaloids, Antihypertensive Agents, Tricyclic Antidepressants, Cardiac Glycosides, CNS Stimulants, and Urinary Alkalinizers
Specific interacting medicines (if explicitly listed) Acetazolamide, Digoxin, Ergotamine, and specific MAOIs such as Linezolid
Mechanistic basis of interactions (only if stated in label) Alteration of renal clearance due to changes in urinary pH; Sympathomimetic activity leading to additive pressor effects; Partial reversal of hypotensive actions; Increased risk of dysrhythmias
Timing-based interaction rules (if applicable) Co-administration is prohibited while on MAOI therapy and for a mandatory waiting period of at least 14 days after stopping MAOI treatment
Population-specific interaction notes (if applicable) Caution is noted in patients with moderate to severe renal impairment due to the potential for a decreased elimination rate and increased exposure
Interaction-related restrictions Prohibited co-administration with MAOIs, other Sympathomimetic Decongestants, and certain Ergot Alkaloids

Interaction classifications (high-level)

Category Description based on Official Documents
Interaction severity classification (as defined in official documents) Contraindicated (e.g., with MAOIs, Ergot Alkaloids); Significant Interaction (e.g., with Antihypertensives, Cardiac Glycosides)
Regulatory basis (EMA / FDA / etc.) FDA DailyMed, EMA SmPC, TGA Product Information
Interaction-context constraints (as defined in official documents) The MAOI prohibition applies concurrently and for a post-discontinuation period of 14 days. Alcohol risk is noted when combined with products containing CNS depressants

Resulting interaction structure

Official interaction statements:

  • Co-administration with MAOIs is strictly contraindicated due to the official risk of hypertensive crisis, necessitating a mandatory 14-day separation window.
  • Pseudoephedrine's sympathomimetic action may partially reverse the hypotensive action of blood pressure regulators, a documented pharmacodynamic interaction.
  • Substances that increase the urinary pH (e.g., Acetazolamide, Citrates) are officially documented to decrease the rate of elimination of pseudoephedrine, resulting in increased systemic exposure.
  • An increased risk of dysrhythmias is officially documented when used with Cardiac Glycosides.

Connection to the overall interaction profile: The regulatory profile is defined by contraindicated combinations with MAOIs, establishing a strict timing-separation requirement. It also details pharmacodynamic interference with cardiovascular medicines and a recognized pharmacokinetic pattern where substances that alter urinary pH officially decrease the drug's elimination rate.

Mechanism of Action

Activation of Vascular Alpha-1 Adrenergic Receptors

The mechanism of action initiates at the molecular level by engaging the alpha-1 (alpha1) adrenergic receptors located on the smooth muscle of blood vessels in the nasal and sinus lining. The active ingredient functions as a sympathomimetic agent, both directly activating these receptors (agonism) and promoting the release of endogenous norepinephrine (NE). This interaction initiates the cellular signaling cascade that characterizes its mechanism of action.


Induction of Vasoconstriction and Mucosal Shrinkage

Activation of the alpha1 receptors leads to increased intracellular calcium, which forces the vascular smooth muscle cells to contract. This contraction results in vasoconstriction—the narrowing of the blood vessels—which reduces local blood flow and limits the leakage of fluid into the surrounding tissues. This physiological change causes the swollen, engorged mucosal membranes to shrink (detumesce), which is the physiological consequence of the mechanism.


Mechanistic Constraint (Tachyphylaxis)

The indirect adrenergic activity is associated with a mechanistic constraint. Prolonged or frequent stimulation can lead to receptor desensitization and a temporary depletion of the local NE supply. This results in a phenomenon known as tachyphylaxis, in which sustained receptor activation or neurotransmitter depletion leads to a diminished physiological response.

Dosage and Administration Information

How Sinustop (Pseudoephedrine HCl) is Used

The usage of Sinustop, which contains pseudoephedrine hydrochloride, follows specific directions to ensure proper administration. This medicine is intended only for oral administration. It is generally used on a short-term basis, with administration typically not exceeding seven consecutive days for self-medication.


Dosing and Frequency

Dosing is determined by the formulation, but the maximum intake of pseudoephedrine hydrochloride must not surpass 240 mg within any 24-hour period.

Formulation Standard Adult Dose (ge 12 years) Frequency Pattern
Immediate-Release 60 mg Every 4 to 6 hours (as needed)
Extended-Release (12-Hour) 120 mg Every 12 hours (q12h)
Extended-Release (24-Hour) 240 mg Once daily (q24h)

Administration Requirements

Sinustop may be taken with or without food. However, immediate-release formulations are generally recommended to be taken several hours before bedtime to avoid potential sleeplessness.

Special Handling for Formulations:

  • Extended-Release Tablets: These forms must be swallowed whole and should not be crushed, chewed, or divided. Altering the tablet compromises the controlled-release mechanism.
  • Liquid Forms: Dosage must be accurately measured using a calibrated measuring device supplied with the product.

Missed Doses: If a dose is missed, the patient should take the next required dose at the usual time, ensuring the minimum prescribed time interval between doses is maintained. A double dose should not be taken to compensate for a missed one.

Recent Clinical Evidence

Research evidence / Overview of studies for Sinustop

Evidence for Temporary Relief of Nasal and Sinus Congestion

The evidence base for the active ingredient in Sinustop, Pseudoephedrine, primarily consists of double-blind, placebo-controlled Randomized Controlled Trials (RCTs), supplemented by systematic reviews and meta-analyses. These studies were used in research exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations, such as the common cold and allergic rhinitis (hay fever). Researchers have specifically examined outcomes related to physical discomfort linked to nasal and sinus blockage.

In these trials, studies explored outcomes related to both patient-reported perceived discomfort and objective measures of function, like monitoring changes in physical nasal airflow. The findings describe patterns observed in the studies related to measured changes in temporary symptom changes related to congestion, especially during the hours immediately following a single dose. Research highlights changes measured during the study period, which were reported as measurements that differed from the patterns seen in the placebo groups. However, when examining multi-day treatment courses, findings were mixed or described as heterogeneous across different systematic reviews. This research provides insight into short-term changes, but findings describe group patterns, not personal outcomes.

Research on the Duration of Relief

Research exploring short-term symptom changes typically involves single-dose observation periods, where the outcomes related to episodic or acute changes were monitored over four to eight hours. This approach is relevant in trials assessing short-term or episodic symptom patterns, providing context related to when changes were observed. Some studies monitored outcomes over intermediate periods, with follow-up durations limited to around seven days of continuous use. This research provides insight into short-term changes but long-term effects are not fully established.

Evidence in Specific Patient Groups

Sinustop's active ingredient was evaluated in specific patient groups, including pediatric cohorts (children aged 6 to 11 years). These trials assessed short-term outcomes related to physical discomfort in children experiencing symptoms associated with conditions involving periods of heightened symptoms. For older adult populations, specific data for certain groups remain insufficient. Although the medicine was studied in general adult populations, data regarding short-term changes in individuals over the age of 65 is limited. Subgroup findings remain uncertain, and results apply primarily to the broader adult populations studied in the main RCTs.

What is Still Uncertain About Sinustop Research

The primary limitation is that long-term effects are not fully established, as follow-up durations were limited across the core body of evidence. Furthermore, the certainty remains low regarding the clinical significance of some measurements, especially those from multi-dose studies, where findings were mixed among systematic reviews. Comparative evidence exploring outcomes against other available decongestant agents is often lacking. Evaluations of the overall evidence quality vary across studies, underscoring that research is ongoing.

Key Studies & References

  1. Label: Pseudoephedrine HCl Tablet, Film Coated (30 mg) - DailyMed (FDA Regulatory Basis)

Frequently Asked Questions (FAQ)

Common questions about Sinustop (FAQ)


Q: What is the longest period of time someone can take Sinustop?

A: Official product information indicates that this medicine is generally intended for short-term use. Regulatory guidance for self-medication generally describes administration periods that typically do not exceed seven consecutive days.


Q: Can people with high blood pressure safely use Sinustop?

A: Regulatory guidance advises individuals with high blood pressure to ask a healthcare provider before starting this medicine. In certain cases, particularly those involving severe hypertension, the active ingredient is listed as a contraindication in the official product information.


Q: Are pregnant or breastfeeding women generally allowed to use Sinustop?

A: Regulatory guidance suggests that this medicine is generally not recommended for use during pregnancy, especially during the first trimester. Official information notes caution regarding use by breastfeeding women because the active ingredient can be excreted into human milk and may potentially affect milk supply.


Q: Are there official warnings about combining Sinustop with certain types of antidepressants?

A: Official interaction statements note that combining this medicine with Monoamine Oxidase Inhibitors (MAOIs) is strictly prohibited. The regulatory profile establishes a waiting period of at least 14 days after stopping MAOI treatment before starting Sinustop. Caution is also noted when using the drug alongside Tricyclic Antidepressants.


Q: What official documents say about combining Sinustop with alcohol?

A: Official regulatory documents note that the risk of certain side effects, such as dizziness, may be increased when combined with alcohol, particularly if the Sinustop product also contains Central Nervous System (CNS) depressants.


Q: Is Sinustop designed for short-term or long-term relief?

A: The medicine is officially indicated for the temporary relief of symptoms and is intended for use on a short-term basis. Studies and official information indicate that long-term effects are not fully established due to limitations in the duration of follow-up in core research trials.


Q: Can people with kidney or liver problems take Sinustop?

A: Official safety information notes caution for patients who have severe renal impairment (kidney problems) or severe hepatic impairment (liver problems). These conditions may affect how the body processes and eliminates the medicine.


Q: Can Sinustop affect mood or cause anxiety?

A: Regulatory safety information lists several related central nervous system effects, including anxiety and nervousness, as reported side effects.


Q: Is Sinustop a cold medicine or an allergy medicine?

A: Official indications state that this medicine is used for the temporary relief of symptoms associated with both the common cold and allergic rhinitis, such as hay fever.


Q: Can Sinustop be taken on an empty stomach?

A: Official administration instructions state that Sinustop may be taken with or without food.


Q: How long does it usually take for Sinustop to start working?

A: Information from clinical pharmacology studies indicates that the onset of action for immediate-release forms is generally observed to begin within approximately 30 minutes.


Q: Is it okay to drive after taking Sinustop?

A: Official patient counseling states that individuals experiencing side effects such as dizziness, nervousness, or restlessness, are advised to avoid engaging in tasks that require complete mental alertness, such as driving or operating machinery.


Q: Does Sinustop cause drowsiness or fatigue?

A: The active ingredient is known for its stimulant effects, meaning it is not commonly associated with causing drowsiness. However, documented side effects do include dizziness.


Q: I heard Sinustop can make you feel jittery—is that true?

A: Official safety documents list nervousness and restlessness as reported side effects. These effects are related to the active ingredient’s central nervous system stimulant properties.


Q: Are there any common foods or drinks that should be avoided while using Sinustop?

A: Regulatory guidance suggests that consuming large amounts of caffeine may be avoided, as this may increase the risk of experiencing some side effects associated with the medicine.


Q: Does Sinustop interact with common pain relievers like ibuprofen?

A: Official interaction maps do not list common over-the-counter pain relievers, such as ibuprofen, as having a major or significant interaction that would require avoidance.


Q: Is Sinustop safe for children under 12?

A: Official regulatory guidance notes that the medicine is contraindicated for use in children under 6 years of age. Dosing instructions are available for children aged 6 to 11 years, and long-acting forms are typically not recommended for those under 12.


Q: Are there different strengths of Sinustop available?

A: Official regulatory documents describe different standard strengths and formulations for the active ingredient, including immediate-release and various extended-release doses.


Q: Why is Sinustop sometimes used for sinus headaches?

A: The medicine is officially indicated for the temporary relief of nasal congestion and sinus pressure. Relief of these symptoms may correspond to the alleviation of the discomfort associated with a sinus headache.


Q: Is Sinustop known to cause insomnia or difficulty sleeping?

A: Official safety information explicitly lists insomnia (trouble sleeping) and restlessness as reported side effects.


Q: Does regulatory research show Sinustop is non-addictive?

A: Official product labels do not typically make explicit claims that the drug is 'non-addictive.' Research mainly focuses on the short-term effectiveness of the medicine.


Q: Can Sinustop cause a 'rebound' effect if stopped suddenly?

A: The phenomenon known as 'rebound congestion,' where symptoms worsen after stopping the medicine, is primarily documented as a risk associated with topical nasal spray decongestants, not typically with oral pseudoephedrine.


Q: Are there specific medical conditions that prevent someone from using Sinustop?

A: Official product information lists several medical conditions where the medicine is contraindicated or used with caution. These include severe hypertension (high blood pressure), severe coronary artery disease, narrow-angle glaucoma, and urinary retention.


Q: Can Sinustop be taken with daily vitamins or supplements?

A: Regulatory guidance states that individuals should inform a healthcare provider about all products being used, which includes any daily prescription or over-the-counter medicines, herbal products, vitamins, and mineral supplements.


Q: Is Sinustop suitable for older adults?

A: Official safety information indicates that adults 65 years of age and older are advised to ask a healthcare provider before using this medicine. Older adults may potentially have a stronger reaction to the medicine.


Q: What kind of evidence is there regarding Sinustop's long-term use?

A: The body of research has established findings regarding short-term symptom changes, but it has also noted that the long-term effects are not fully established due to limitations in the duration of follow-up in the core studies.


Q: What if Sinustop doesn't seem to be working for me after a few days?

A: Regulatory guidance suggests that if symptoms persist or worsen after seven days of short-term use, it may indicate a need to consult a healthcare provider.


Q: Is there a link between Sinustop and increased heart rate?

A: The drug's safety information lists an increased heart rate (tachycardia) and elevated blood pressure as reported side effects.


Q: Do studies support the use of Sinustop for chronic sinus issues?

A: Clinical studies focus on the temporary relief of symptoms associated with episodic or acute manifestations, such as those from the common cold or allergic rhinitis. The research evidence does not specifically support the medicine's use for long-term or chronic sinus issues.


Q: What are the most commonly reported less serious side effects of Sinustop?

A: Official adverse reaction reports commonly list effects such as nervousness, restlessness, insomnia (difficulty sleeping), dry mouth, and headache.


Q: Is Sinustop gluten-free or suitable for people with allergies?

A: The suitability of the product for specific allergies, such as gluten, depends entirely on the specific formulation manufactured. All inactive ingredients (excipients) are required to be listed on the official product label.


Q: Does Sinustop affect blood sugar levels?

A: Regulatory guidance advises that individuals with diabetes may need to consult a healthcare provider before using the medicine. The sympathomimetic effects of the drug can potentially affect blood glucose control.


Q: Are there any known severe or rare side effects mentioned in the drug's safety information?

A: Official safety information includes warnings about rare but severe adverse events, such as a severe hypertensive crisis (very high blood pressure) and serious psychological effects like hallucinations.


Q: What specific ingredients in Sinustop are responsible for the main effect?

A: The active ingredient in Sinustop, which is responsible for the main decongestant effect, is pseudoephedrine hydrochloride.


Q: What should I do if I accidentally take two doses close together?

A: Regulatory guidelines advise against doubling a dose to make up for a missed one. If more than the recommended amount of the medicine is taken, the patient should immediately contact a poison control center or seek emergency medical help.


Q: Do clinical trials for Sinustop include diverse patient populations?

A: Clinical studies have been conducted in pediatric cohorts (children 6 to 11 years) as well as the general adult population. However, official research documents indicate that specific data for older adult populations is limited.


Q: Can Sinustop cause dryness of the mouth or nose?

A: Dry mouth is listed in the official adverse reactions reports as a commonly experienced side effect of the medicine.


Q: Is it normal to feel slightly dizzy when first starting Sinustop?

A: Dizziness is a documented side effect of the medicine and is listed in the official safety information.


Q: Does Sinustop contain any common allergens like lactose?

A: The presence of inactive ingredients, such as lactose, depends on the specific product formulation. The full list of all inactive ingredients is required to be included on the official product label.


Q: Why do some people say Sinustop makes them feel nervous?

A: Official safety information lists nervousness as a common reported side effect, which is related to the drug's stimulant properties.


Q: Is there evidence that Sinustop is more effective at night or during the day?

A: There is no official research that indicates the medicine is differentially more effective at night or during the day. Immediate-release formulations are sometimes described as being taken several hours before bedtime to help minimize potential sleeplessness.


Q: Can Sinustop be crushed or split if the pill is too large?

A: Regulatory administration requirements strictly state that Extended-Release Tablets must be swallowed whole. Altering this type of tablet (by crushing, chewing, or splitting) can compromise the controlled-release mechanism.


Q: Are there specific age restrictions for Sinustop's use?

A: Official regulatory guidance notes that the product is contraindicated for use in children under 6 years of age.


Q: What research exists about Sinustop's effectiveness compared to placebo?

A: The evidence base for the medicine includes double-blind, placebo-controlled Randomized Controlled Trials (RCTs). These studies have reported measured changes in symptoms that differed from the patterns observed in the placebo groups.


Q: Is Sinustop only available by prescription?

A: The active ingredient in Sinustop is available in both Over-the-Counter (OTC) and Prescription (Rx) formulations, which are subject to different regulatory requirements regarding their sale.


How should Sinustop be stored and disposed of?

How to Store and Dispose of Sinustop (Pseudoephedrine HCl)

Sinustop, containing pseudoephedrine hydrochloride, must be stored and handled according to its official regulatory labeling to ensure product stability and safety.

Storage Requirements

Condition Regulatory Stipulation
Temperature Store at controlled room temperature, 25 C (77 F). Permitted excursions are 15 C to 30 C (59 F to 86 F).
Container Keep in the original container and do not use if the blister unit is torn or broken.
Protection Keep in a dry place, away from excessive heat and moisture. Do not freeze.
Child Safety The medication must be kept out of reach of children.

Disposal Instructions

Unused or expired Sinustop should be disposed of via a drug take-back program. If a program is unavailable, mix the medicine with an unappealing substance (e.g., dirt) in a sealed bag before disposal in household trash. It is not recommended to flush this medicine down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sinustop found in:

A-Z Index: